Skip to Content

Delavirdine Mesylate

Class: HIV Nonnucleoside Reverse Transcriptase Inhibitors
- Reverse Transcriptase Inhibitors
VA Class: AM800
Chemical Name: 1-[3-[(1-Methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-piperazinemonomethanesulfonate
Molecular Formula: C22H28N6O3S•CH4 O3S
CAS Number: 147221-93-0
Brands: Rescriptor

Medically reviewed by Last updated on Feb 12, 2019.


Antiretroviral; HIV nonnucleoside reverse transcriptase inhibitor (NNRTI).1 200

Uses for Delavirdine Mesylate

Treatment of HIV Infection

Treatment of HIV-1 infection in adults;1 usually used in conjunction with 2 HIV nucleoside reverse transcriptase inhibitors (NRTIs).1 5

Experts state delavirdine not recommended for initial treatment regimens in antiretroviral-naive adults because of inferior virologic efficacy and inconvenient dosing regimen.200

Data insufficient comparing delavirdine regimens to the preferred 3-drug regimens for initial treatment in antiretroviral-naive adults; consider that the proportion of clinical study patients responding to regimen of delavirdine and 2 NRTIs with sustained plasma HIV-1 levels <400 copies/mL over 1 year has been relatively low.1

Delavirdine Mesylate Dosage and Administration


Oral Administration

Administer orally 3 times daily with or without food.1

For patients unable to swallow tablets, 100-mg tablets may be administered as slurry or dispersion in water.1 To prepare dispersion containing 400 mg, place four 100-mg tablets in a glass containing ≥90 mL of water, let stand for a few minutes, then stir until a uniform dispersion occurs.1 6 Consume dispersion promptly; rinse glass with more water and swallow the rinse.1

The 200-mg tablets are not readily dispersed in water1 33 and should be swallowed intact.1

Patients with achlorhydria should take delavirdine with an acidic beverage (e.g., orange or cranberry juice).1


Available as delavirdine mesylate; dosage expressed in terms of delavirdine mesylate.1

Pediatric Patients

Treatment of HIV Infection

Adolescents ≥16 years of age: 400 mg 3 times daily.1


Treatment of HIV Infection

400 mg 3 times daily.1

Special Populations

Hepatic Impairment

Data insufficient to make dosage recommendation for patients with hepatic impairment;200 use with caution.1 200

Renal Impairment

Dosage adjustments not needed.200

Geriatric Patients

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1

Cautions for Delavirdine Mesylate


  • Known hypersensitivity to delavirdine or any ingredient in the formulation.1

  • Concomitant use with drugs highly dependent on CYP3A for metabolism and for which elevated plasma concentrations are associated with serious and/or life-threatening events (e.g., alprazolam, cisapride, ergot alkaloids, midazolam, pimozide, triazolam).1 (See Specific Drugs under Interactions.)




Concomitant use with certain drugs not recommended (e.g., lovastatin, simvastatin, rifampin, rifabutin, phenytoin, phenobarbital, carbamazepine, St. John’s wort) or requires particular caution (sildenafil).1 (See Specific Drugs under Interactions.)

Sensitivity Reactions

Dermatologic Reactions

Severe rash, erythema multiforme, Stevens-Johnson syndrome reported; these severe reactions resolved after drug discontinued.1

Patients experiencing severe rash or rash accompanied by fever, blistering, oral lesions, conjunctivitis, swelling, or muscle or joint aches should discontinue delavirdine and seek medical assistance.1

Mild rash also reported.1 Rash usually occurs during first month of therapy, mainly on upper body and proximal arms with decreasing intensity of lesions on neck and face and progressively less on rest of trunk and limbs.1

Rash usually resolves in <2 weeks and generally does not require dosage reduction or contraindicate use of the drug.1 If delavirdine therapy is interrupted because of rash, most patients are able to resume therapy with the drug.1

Mild or moderate rash can be treated with diphenhydramine hydrochloride, hydroxyzine hydrochloride, and/or topical corticosteroids.1

General Precautions

HIV Resistance

Possibility of HIV resistant to delavirdine and possible cross-resistance to other NNRTIs.1

Adipogenic Effects

Redistribution or accumulation of body fat, including central obesity, dorsocervical fat enlargement (“buffalo hump”), peripheral wasting, facial wasting, breast enlargement, and general cushingoid appearance reported in patients receiving antiretroviral therapy.1 Mechanisms and long-term consequences unknown; causal relationship not established.1

Immune Reconstitution Syndrome

During initial treatment, patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium complex [MAC], M. tuberculosis, cytomegalovirus [CMV], Pneumocystis jirovecii [formerly P. carinii]); this may necessitate further evaluation and treatment.1

Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barré syndrome) have been reported to occur in the setting of immune reconstitution; time to onset is variable and can occur many months after initiation of antiretroviral therapy.1

Specific Populations


Category C.1

Antiretroviral Pregnancy Registry at 800-258-4263 or [Web].1 202


Distributed into milk in rats; not known whether distributed into human milk.1

Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant.1 202

Pediatric Use

Safety and efficacy not established in children <16 years of age.1

Geriatric Use

Insufficient experience in those ≥65 years of age to determine whether they respond differently than younger adults.1

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1

Hepatic Impairment

Extensively metabolized in liver; use with caution in those with hepatic impairment.1

Common Adverse Effects

Rash, asthenia/fatigue, nausea.1

Interactions for Delavirdine Mesylate

Metabolized by CYP3A and CYP2D6.1

Inhibits CYP3A and, to a lesser extent, 2C9, 2D6, and 2C19.1

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Pharmacokinetic interactions likely with drugs that are inhibitors, inducers, or substrates of CYP3A;1 possible alteration in metabolism of delavirdine and/or other drug.1

Specific Drugs





Possible increased amphetamine concentrations1

Use with caution1

Antacids, aluminum- or magnesium-containing

Decreased delavirdine concentrations1

Take delavirdine at least 1 hour before or after antacids1

Antiarrhythmic agents (amiodarone, flecainide, systemic lidocaine, propafenone, quinidine)

Possible increased concentrations of antiarrhythmic agent; potential for serious or life-threatening effects (e.g., cardiac arrhythmias) with certain agents1

Use concomitantly with caution; monitor plasma concentrations of antiarrhythmic agent1

Anticoagulants, oral

Possible increased warfarin concentrations 1

Monitor INR; adjust warfarin dosage accordingly1

Anticonvulsants (carbamazepine, phenytoin, phenobarbital)

Decreased delavirdine concentrations; possible loss of virologic response and development of resistance to the antiretroviral and other NNRTIs1

Do not use concomitantly with delavirdine1

Antifungals, azoles (fluconazole, ketoconazole, voriconazole)

Fluconazole: Pharmacokinetic interaction not clinically important1


Ketoconazole: Increased delavirdine concentrations1


Voriconazole: Increased voriconazole concentrations53

Voriconazole: Monitor frequently for voriconazole adverse effects53

Antimycobacterials (rifabutin, rifampin, rifapentine)

Rifabutin: Decreased delavirdine AUC; increased rifabutin AUC1

Rifampin: Decreased delavirdine AUC 1

Possible loss of virologic response and increased risk of delavirdine or NNRTI resistance1

Concomitant use with rifabutin, rifampin, or rifapentine not recommended1 34 35 200


No in vitro evidence of antagonistic antiretroviral effects203


Benzodiazepines (alprazolam, midazolam, triazolam)

Potential for serious and/or life-threatening adverse effects such as prolonged or increased sedation or respiratory depression1

Concomitant use contraindicated1

Calcium-channel blocking agents (amlodipine, diltiazem, felodipine, isradipine, nifedipine, nimodipine, nisoldipine, verapamil)

Possible increased concentrations of calcium-channel blocking agent1

Use concomitantly with caution; clinical monitoring recommended1


Potential for serious or life-threatening reactions (e.g., cardiac arrhythmias)1

Concomitant use contraindicated1


Interaction unlikely1


Corticosteroids (dexamethasone, fluticasone)

Dexamethasone: Possible decreased delavirdine concentrations 1

Dexamethasone: Use with caution; delavirdine may be less effective1


Fluticasone (orally inhaled, intranasal): Possible increased fluticasone concentrations1

Fluticasone (orally inhaled, intranasal): Use concomitantly with caution; consider alternative to fluticasone, especially when long-term corticosteroid therapy is anticipated1


No in vitro evidence of antagonistic antiretroviral effects204



Decreased delavirdine concentrations if given at same time as buffered didanosine preparations;1 clinically important pharmacokinetic interaction not observed when buffered didanosine administered 1 hour after delavirdine1

In vitro evidence of additive to synergistic antiretroviral effects1

Administer buffered didanosine (pediatric oral solution admixed with antacid) at least 1 hour before or after delavirdine1



Do not use concomitantly1 200


In vitro evidence of additive or synergistic antiretroviral effects218

Ergot alkaloids (dihydroergotamine, ergonovine, ergotamine, methylergonovine)

Concomitant use contraindicated1


Hormonal contraceptives: Possible increased concentrations of ethinyl estradiol1

Clinical importance unknown1


Possible increased etravirine concentrations214

Do not use concomitantly1 200 214


Increased delavirdine trough concentrations1



Studies using amprenavir (active metabolite of fosamprenavir) indicate increased amprenavir concentrations and AUC and possible decreased delavirdine concentrations and AUC;205 possible decreased antiretroviral efficacy and increased risk of antiretroviral resistance205

In vitro evidence of synergistic antiretroviral effects205

Fosamprenavir (with or without low-dose ritonavir): Concomitant use contraindicated205

Histamine H2-receptor antagonists (cimetidine, famotidine, nizatidine, ranitidine)

Possible decreased GI absorption of delavirdine1

Long-term concomitant use not recommended1

HMG-CoA reductase inhibitors (statins)

Atorvastatin, fluvastatin, lovastatin, simvastatin: Possible increased concentrations of the antilipemic agents; increased risk of myopathy and/or rhabdomyolysis1

Atorvastatin: Use lowest possible atorvastatin dosage;1 consider using pravastatin instead1

Fluvastatin: Use lowest possible fluvastatin dosage;1 consider using pravastatin instead1

Lovastatin: Do not use concomitantly1

Simvastatin: Do not use concomitantly1

Immunosuppressive agents (cyclosporine, sirolimus, tacrolimus)

Potential for increased concentrations of cyclosporine, sirolimus, or tacrolimus1

Monitor plasma concentrations of immunosuppressive agent1


Delavirdine inhibits indinavir metabolism and may increase indinavir concentrations and AUC; no effect on delavirdine pharmacokinetics1 206

Use reduced indinavir dosage of 600 mg every 8 hours with usual delavirdine dosage (400 mg 3 times daily)1 206


In vitro evidence of additive or synergistic antiretroviral effects1



Possible increased lopinavir concentrations1

Appropriate dosages for concomitant use with respect to safety and efficacy not established1

Macrolides (clarithromycin)

No change in delavirdine pharmacokinetic; increased clarithromycin AUC1

Dosage adjustments not needed in patients with normal renal function; reduce clarithromycin dosage by 50% in patients with Clcr 30–60 mL/minute and by 75% in patients with Clcr <30 mL/minute1


Possible increased maraviroc concentrations1

No in vitro evidence of antagonistic antiretroviral effects224

Recommended maraviroc dosage is 150 mg twice daily in patients receiving delavirdine224


Possible increased methadone concentrations1

Methadone dosage may need to be reduced1


Decreased delavirdine concentrations and AUC; increased nelfinavir concentrations and AUC1 208

In vitro evidence of synergistic antiretroviral effects208

Appropriate dosages for concomitant use with respect to safety and efficacy not established1 208


Do not use concomitantly1 200


Potential for serious or life-threatening reactions (e.g., cardiac arrhythmias)1

Concomitant use contraindicated1

Proton-pump inhibitors (omeprazole, lansoprazole)

Possible decreased GI absorption of delavirdine1

Long-term concomitant use not recommended1

Quinupristin and dalfopristin

Possible increased delavirdine concentrations39



In vitro evidence of additive to synergistic antiretroviral effects225


Possible increased rilpivirine concentrations226

Do not use concomitantly1 200 226


Increased ritonavir concentrations1

Appropriate dosages for concomitant use with respect to safety, efficacy, and pharmacokinetics not established1


Increased saquinavir concentrations and AUC;1 210 no clinically important effect on delavirdine concentrations1

Ritonavir-boosted saquinavir: Concomitant use not evaluated210

Appropriate dosages for concomitant use with respect to safety, efficacy, and pharmacokinetics not established1 210


Possible increased simeprevir concentrations187

Concomitant use not recommended187

St. John’s wort (Hypericum perforatum)

Possible loss of virologic response and increased risk of delavirdine or NNRTI resistance1

Do not use concomitantly1


Possible increased sildenafil concentrations and increased risk of sildenafil-associated adverse effects (e.g., hypotension, visual changes, prolonged erection)1

Use caution; do not exceed 25 mg once every 48 hours1


No in vitro evidence of antagonistic antiretroviral effects221



In vitro evidence of additive antiretroviral effects211



Possible increased trazodone concentrations1

Adverse effects (nausea, dizziness, hypotension, syncope) reported with concomitant use of trazodone and other CYP3A inhibitors (e.g., ritonavir)1

Use with caution; consider using decreased trazodone dosage1


No pharmacokinetic interaction1 6

In vitro evidence of additive or synergistic antiretroviral effects1


Delavirdine Mesylate Pharmacokinetics



Rapidly absorbed from GI tract; peak plasma concentrations achieved within 1 hour.1

Bioavailability of delavirdine tablets is 85% relative to that of an oral solution of the drug.1 Bioavailability of 100-mg tablets is increased by approximately 20% when allowed to disintegrate in water and administered as a slurry.1


Food does not have an appreciable effect on plasma concentrations or AUC.1



Not fully characterized.1

Distributed into CSF in low concentrations.1

Distributed into milk in rats; not known whether distributed into human milk.1

Plasma Protein Binding




Metabolized by CYP3A and CYP2D6.1

Elimination Route

Excreted in feces (44%) and urine (51%).1


5.8 hours.1





20–25°C in tight container; protect from high humidity.1

Actions and Spectrum

  • Pharmacologically related to other NNRTIs (e.g., efavirenz, etravirine, nevirapine, rilpivirine); differs structurally from these drugs; also differs pharmacologically and structurally from other currently available antiretrovirals.1 6 7 8 10 11 12 214

  • Active against HIV-1; inactive against HIV-2.1 8 31

  • Inhibits replication of HIV-1 by interfering with viral RNA- and DNA-directed polymerase activities of reverse transcriptase.1 6 7 8 10 11 12 15

  • HIV-1 with reduced susceptibility to delavirdine have been selected in vitro and have emerged during therapy with the drug.1 6 8 19 31

  • Strains of HIV-1 resistant to delavirdine may be cross-resistant to some other NNRTIs.1 6 7

  • Cross-resistance between delavirdine and NRTIs unlikely since the drugs bind at difference sites on reverse transcriptase and have different mechanisms of action.1 15 Cross-resistance between delavirdine and HIV protease inhibitors (PIs) unlikely since the drugs have different target enzymes and mechanisms of action.1

Advice to Patients

  • Critical nature of compliance with HIV therapy and importance of remaining under the care of a clinician.1 Importance of taking as prescribed; do not alter or discontinue antiretroviral regimen without consulting clinician.1

  • Importance of using in conjunction with other antiretrovirals—not for monotherapy.1

  • Antiretroviral therapy is not a cure for HIV infection; opportunistic infections and other complications associated with HIV disease may still occur.1

  • Advise patients that effective antiretroviral regimens can decrease HIV concentrations in blood and genital secretions and strict adherence to such regimens in conjunction with risk-reduction measures may decrease, but cannot absolutely eliminate, the risk of secondary transmission of HIV to others.200 Importance of continuing to practice safer sex (e.g., using latex or polyurethane condoms to minimize sexual contact with body fluids), never sharing personal items that can have blood or body fluids on them (e.g., toothbrushes, razor blades), and never reusing or sharing needles.1 200

  • Importance of reading patient information provided by the manufacturer.1

  • Importance of patients with achlorhydria taking delavirdine with an acidic beverage.1

  • If a dose is missed, the next dose should be taken as soon as possible.1 If a dose is skipped, do not take a double dose to make up for the missed dose.1

  • Importance of discontinuing delavirdine and consulting a clinician if severe rash or rash accompanied by fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches occurs.1

  • Redistribution/accumulation of body fat may occur, with as yet unknown long-term health effects.1

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal products (e.g., St. John’s wort), and any concomitant illnesses.1

  • Advise patients receiving PDE5 inhibitors (e.g., sildenafil) that they may be at increased risk of PDE5 inhibitor-associated adverse effects (e.g., hypotension, visual disturbances, priapism) and that any symptoms should be promptly reported to their clinician.1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 Advise HIV-infected women not to breast-feed.1

  • Importance of advising patients of other important precautionary information.1 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Delavirdine Mesylate


Dosage Forms


Brand Names




100 mg



200 mg



AHFS DI Essentials™. © Copyright 2019, Selected Revisions February 12, 2015. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.


1. ViiV Healthcare. Rescriptor (delavirdine mesylate) tablets prescribing information. Research Triangle Park, NC; 2012 Aug.

5. Friedland GH, Pollard R, Griffith B et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease and CD4 counts of 100 to 500 cells/mm3 (ACTG 261). J Acquir Immune Defic Syndr. 1999; 21:281-92.

6. Pharmacia & Upjohn, Kalamazoo, MI: Personal communication.

7. Moyle GJ. Resistance to antiretroviral compounds: implications for the clinical management of HIV infection. Immunol Infect Dis. 1995; 5:170-82.

8. Freimuth WW. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chemother. 1996; 4:279-89.

9. Dueweke TJ, Poppe SM, Romero DL et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 1993; 37:1127-31.

10. Althaus IW, Chou JJ, Gonzales AJ et al. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J Biol Chem. 1993; 268:6119-24.

11. Althaus IW, Chou JJ, Gonzales AJ et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol. 1994; 47:2017-28.

12. Dueweke TJ, Kezdy FJ, Waszak GA et al. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem. 1992; 267:27-30.

13. Watkins BA, Klotman ME, Gallo RC. Human Immunodeficiency Viruses. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:1590-606.

14. Sardana VV, Emini EA, Gotlib L et al. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem. 1992; 267:17526-30.

15. Gu Z, Quan Y, Li Z et al. Effects of nonnucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. J Biol Chem. 1995; 270:31046-51.

16. Vasudevachari MB, Battista C, Lane HC et al. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology. 1992; 190:269-77.

18. Chong KT, Pagano PJ. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Res. 1997; 34:51-63.

19. Demeter LM, Meehan PM, Morse G et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr. 1997; 14:136-44.

20. Kohlstaedt LA, Wang J, Friedman JM et al. Crystal structure at 3.5 resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992; 256:1783-90.

21. Spence RA, Kati WM, Anderson KS et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 1995; 267:988-93.

26. AIDS Clinical Trials Information Service (ACTIS) (database). 2000 Jun. From web site.

27. Barin F, Couroue AM, Pillonel J et al. Increasing diversity of HIV-1M serotypes in French blood donors over a 10-year period (1985-1995). AIDS. 1997; 11:1503-8.

30. Reviewers’ comments (personal observations).

31. Witvrouw M, Pannecourque C, Van Laethem K et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 1999; 13:1477-83.

33. Rohrs BR, Thamann TJ, Gao P et al. Tablet dissolution affected by a moisture mediated solid-state interaction between drug and disintegrant. Pharm Res. 1999; 16:1850-6.

34. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations MMWR. 1998; 47(No. RR-20).

35. Centers for Disease Control and Prevention. Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep. 2000; 49:185-9.

36. Borin MT, Cox SR, Herman BD et al. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrob Agents Chemother. 1997; 41:1892-7.

37. Demeter LM, Shafer RW, Meehan PM et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 2000; 44:794-7.

38. Mills G, Morgan J, hales G et al. Acute hypersensitivity with delavirdine. Antivir Ther. 1999; 4:51.

39. Rhone-Poulenc Rorer Pharmaceuticals Inc. Synercid I.V. (quinupristin and dalfopristin) prescribing information. Collegeville, PA; 1999 Jul.

40. Lumpkin MM, Alpert A. Risk of drug interactions with St. John’s wort and indinavir and other drugs. FDA Public Health Advisory. 2000 Feb 10. From FDA website.

41. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St. John’s wort. Lancet. 2000; 355:547-8.

42. Johne A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999; 66:338-45.

43. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John’s wort. Lancet. 2000; 355:548-9.

45. Yuen N (Agouron Pharmaceuticals, La Jolla, CA). Personal communication; 2000 Aug 4.

47. American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infections. Am J Respir Crit Care Med. 2000; 161:S221-47.

49. Hood R, Hawkins DA, Moyle G et al. Second placebo-controlled study in naive individuals confirms the role of delavirdine in highly active antiretroviral, protease-sparing treatment. Proceedings of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1999.

50. Moyle G, De Cian W, Hawkins D et al. Final 54-week analysis of a placebo-controlled trial (13C) of delavirdine (DLV) plus two nucleoside analogs (NA) versus two NA in drug-naïve and -experienced individuals. Proceedings of the 39th ICAAC. San Francisco, CA: 1999.

52. Smith D, Hales G, Roth N et al. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV Clin Trials. 2001; 2:97-107.

53. Pfizer. Vfend (voriconazole) for injection, tablets, and for oral suspension prescribing information. New York, NY; 2011 Nov.

187. Janssen. Olysio (simeprevir) capsules prescribing information. Titusville, NJ; 2013 Nov.

200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 1, 2014). Updates may be available at HHS AIDS Information (AIDSinfo) website.

202. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States (March 28, 2014). Updates may be available at HHS AIDS Information (AIDSinfo) website.

203. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules and oral powder prescribing information. Princeton, NJ; 2014 Jun.

204. Janssen. Prezista (darunavir) oral suspension and tablets prescribing information. Titusville, NJ; 2014 Apr.

205. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2013 Apr.

206. Merck Sharp & Dohme. Crixivan (indinavir sulfate) capsules prescribing information. Whitehouse Station, NJ; 2014 Jul.

208. ViiV Healthcare. Viracept (nelfinavir mesylate) tablets and oral powder prescribing information. Research Triangle Park, NC; 2012 Apr.

210. Genentech USA. Invirase (saquinavir mesylate) capsules and tablets prescribing information. South San Francisco, CA; 2012 Nov.

211. Boehringer Ingelheim. Aptivus (tipranavir) capsules and oral solution prescribing information. Ridgefield, CT; 2012 Apr.

214. Janssen. Intelence (etravirine) tablets prescribing information. Raritan, NJ; 2012 Mar.

218. Gilead Sciences. Emtriva (emtricitabine) capsules and oral solution prescribing information. Foster City, CA; 2012 Jul.

221. Gilead Sciences. Viread (tenofovir disoproxil fumarate) tablets prescribing information. Foster City, CA; 2013 Oct.

224. ViiV Healthcare. Selzentry (maraviroc) tablets prescribing information. Research Triangle Park, NC; 2014 Mar.

225. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets, chewable tablets, and for oral suspension prescribing information. Whitehouse Station, NJ; 2014 Apr.

226. Janssen Therapeutics. Edurant (rilpivirine) tablets prescribing information. Titusville, NJ; 2014 May.